Elevation Oncology, Inc. (NASDAQ:ELEV) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC raised its position in Elevation Oncology, Inc. (NASDAQ:ELEV) by 33.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 61,467 shares of the company’s stock after acquiring an additional 15,560 shares during the period. SG Americas Securities LLC owned approximately 0.10% of Elevation Oncology worth $35,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Frazier Life Sciences Management L.P. raised its holdings in shares of Elevation Oncology by 102.6% in the third quarter. Frazier Life Sciences Management L.P. now owns 5,993,579 shares of the company’s stock worth $3,596,000 after buying an additional 3,035,000 shares during the last quarter. Sphera Funds Management LTD. raised its holdings in shares of Elevation Oncology by 227.2% in the third quarter. Sphera Funds Management LTD. now owns 1,079,762 shares of the company’s stock worth $648,000 after buying an additional 749,762 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Elevation Oncology in the third quarter worth $260,000. State Street Corp raised its holdings in shares of Elevation Oncology by 13.5% in the third quarter. State Street Corp now owns 1,018,026 shares of the company’s stock worth $611,000 after buying an additional 120,993 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Elevation Oncology by 7.6% in the third quarter. Geode Capital Management LLC now owns 1,110,085 shares of the company’s stock worth $666,000 after buying an additional 78,509 shares during the last quarter. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently issued reports on ELEV shares. William Blair started coverage on shares of Elevation Oncology in a report on Friday, January 3rd. They set an “outperform” rating for the company. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Elevation Oncology in a report on Tuesday, January 14th. JMP Securities reissued a “market outperform” rating and set a $7.00 target price on shares of Elevation Oncology in a report on Thursday, December 19th. Finally, Stephens reissued an “overweight” rating and set a $5.00 target price on shares of Elevation Oncology in a report on Friday, December 6th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $7.20.

Elevation Oncology Trading Up 1.9 %

NASDAQ ELEV opened at $0.67 on Friday. The company has a quick ratio of 17.77, a current ratio of 17.77 and a debt-to-equity ratio of 0.45. Elevation Oncology, Inc. has a 52 week low of $0.50 and a 52 week high of $5.83. The stock has a market capitalization of $39.71 million, a PE ratio of -0.82 and a beta of 1.31. The firm has a 50 day moving average of $0.66 and a two-hundred day moving average of $0.70.

About Elevation Oncology

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.